In a prospective cohort of 89,069 participants tracked over a median 8.8 years (804,111 person-years), objectively measured daytime light exposure above 1916 lux between 7:30–20:30 was associated with a 13% reduction in gastrointestinal cancer incidence (HR 0.87) and a 24% reduction in mortality (HR 0.76). The effect was most striking for pancreatic cancer: adequate light exposure slashed incidence risk by 42% (HR 0.58) and mortality by 53% (HR 0.47). Notably, light exposure's predictive power outperformed sleep quality, diet, depression, and alcohol consumption as a cancer risk factor.
Pancreatic cancer is notoriously difficult to detect early and carries a five-year survival rate below 13%, making any modifiable protective factor of urgent interest. The proposed mechanism — circadian clock synchronization at the tissue and cellular level — is biologically coherent. Disrupted circadian rhythms are known to dysregulate cell-cycle checkpoints, DNA repair timing, and immune surveillance, all of which are cancer-relevant pathways. What distinguishes this study is its use of objective lux measurements rather than self-reported sun exposure, substantially reducing recall bias.
Limitations are real: observational design cannot confirm causality, residual confounding from outdoor activity habits is plausible, and the UK Biobank-likely cohort skews older and whiter. Still, the finding that a chronotherapeutic threshold of ≥2.4 hours at ≥5000 lux maps onto existing light therapy benchmarks adds translational specificity. This is more than incremental — it positions light exposure as a potentially underappreciated, low-cost tool in cancer prevention strategy.
